Herbal granules could cut heart risks after stent surgery
NCT ID NCT07616544
First seen Jun 08, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This study tests whether adding a Chinese herbal medicine called Qidan Xiaoke Granules to standard heart drugs can reduce major heart problems like heart attacks or repeat procedures in people who have had a stent placed. About 164 adults with coronary artery disease will take the granules twice daily for 12 weeks, and researchers will track their heart health for nearly a year. The goal is to see if this herbal approach offers extra protection beyond usual care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Qidan Xiaoke Granules (Chinese herbal compound)
What this could lead to
If successful, this could provide a new, low-cost add-on treatment to reduce heart attacks and hospital readmissions after stent surgery.
What could go wrong
This is a phase 3 trial, but it's relatively small (164 people) and tests a herbal compound, which may have variable quality or unknown interactions. The results may not apply to all heart patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.